Business Context and Reporting Period
This Form 8-K filing by Galectin Therapeutics Inc. reports a corporate governance event dated June 19, 2013, with the announcement made on June 21, 2013. The filing details the appointment of a new Chief Financial Officer and the transition of the outgoing CFO to a consulting role.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- New CFO Annual Salary: $175,000
- New CFO Performance Bonus: 20% of salary
- New CFO Signing Bonus: $10,000
- New CFO Stock Options: 200,000 shares (vesting 2013-2016)
- Outgoing CFO Consulting Options: 25,000 shares (exercise price $3.97)
Material Changes
The primary material change is the leadership transition in the finance department:
- Appointment: Jack W. Callicutt was hired as Chief Financial Officer, effective July 1, 2013.
- Departure/Transition: Thomas A. McGauley will cease serving as CFO on July 1, 2013, and will transition to an independent consultant role until the filing of the Form 10-Q for the quarter ended June 30, 2013.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. It outlines the terms of the employment agreement with Mr. Callicutt, which has an initial term ending December 31, 2016. The agreement includes specific vesting schedules for stock options tied to calendar year-ends.
Investor Verification Checklist
- Verify the closing stock price on July 1, 2013, to determine the exercise price for Mr. Callicutt's 200,000 options.
- Confirm the filing date of the Form 10-Q for the quarter ended June 30, 2013, to determine when Mr. McGauley's consulting options vest.
- Review the company's subsequent filings for any changes to the executive compensation structure or the duration of Mr. McGauley's consulting engagement.